source
- Merck still sees ‘compelling’ outlook for Terns leukemia drugDespite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.BioPharma Dive · 3mo ago↗ source
- UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapyNews of the submission, which would be the first for UniQure’s closely watched treatment, comes as the therapy faces an uncertain future in the U.S.BioPharma Dive · 3mo ago↗ source
- STAT+: FDA wants to exclude weight loss drugs from a compounding listFDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, saying there's no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.